Anika Therapeutics
ANIK
153 hedge funds and large institutions have $406M invested in Anika Therapeutics in 2014 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 65 increasing their positions, 46 reducing their positions, and 31 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 162 → 153 (-9)
13% less capital invested
Capital invested by funds: $465M → $406M (-$59.2M)
26% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 31
26% less call options, than puts
Call options by funds: $3.33M | Put options by funds: $4.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$17.2M |
| 2 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$14.4M |
| 3 |
Millennium Management
New York
|
+$11M |
| 4 |
GAM
Gotham Asset Management
New York
|
+$6.06M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$9.77M |
| 2 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
-$8.93M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$5.23M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$4.78M |
| 5 |
Renaissance Technologies
New York
|
-$4.18M |
ANIK Hedge Fund Activity: Q3 2014 in Review
153 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2014, worth a combined $406M — down 13% from $465M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ANIK and 23 opened new positions — a net loss of 8 holders — while 46 trimmed existing stakes and 65 added.
The largest buyer was Boston Trust Walden, opening a new position worth an estimated $17.2M. The largest seller was Bogle Investment Management, cutting an estimated $9.77M.
- 153 institutional investors held Anika Therapeutics (ANIK) as of Q3 2014, down from 162 in Q2 2014.
- Funds reported $406M of Anika Therapeutics stock for Q3 2014, down 13% quarter-over-quarter.
- 23 funds opened new Anika Therapeutics positions in Q3 2014 and 31 closed out, a net change of -8 holders.
- The largest Anika Therapeutics buyer in Q3 2014 was Boston Trust Walden, an estimated $17.2M added.
- The largest Anika Therapeutics seller in Q3 2014 was Bogle Investment Management, an estimated $9.77M sold.
Based on aggregated 13F filings for Q3 2014.